NCT00086619View on ClinicalTrials.gov

Parathyroid Hormone (PTH) for Osteoporosis in Postmenopausal Women

PHASE2CompletedINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

May 31, 2004

Primary Completion Date

December 31, 2009

Study Completion Date

December 31, 2009

Conditions
Postmenopausal OsteoporosisOsteoporosis
Interventions
DRUG

synthetic hPTH 1-34

Either daily treatment with self-injected hPTH 1-34 or ascending dose treatment at 6-month intervals of hPTH 1-34

Trial Locations (1)

02114

Massachusetts General Hospital, Boston

All Listed Sponsors
collaborator

National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)

NIH

lead

Massachusetts General Hospital

OTHER

NCT00086619 - Parathyroid Hormone (PTH) for Osteoporosis in Postmenopausal Women | Biotech Hunter | Biotech Hunter